Q0240 – Injection, casirivimab and imdevimab, 600 mg

Long description

Injection, casirivimab and imdevimab, 600 mg

Short description

Casirivi and imdevi 600 mg

Pricing indicator

54 Vaccinations

Medicare coverage

C Carrier judgment – coverage decided by the Medicare contractor

BETOS category

O1G Immunizations/Vaccinations

Added

July 30, 2021

Last change

December 13, 2024 – No change

Termination date

December 12, 2024

Nearby Q codes

• Q0221 – Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg
• Q0222 – Injection, bebtelovimab, 175 mg
• Q0224 – Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2 exposure, and who either have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments, and are unlikely to mount an adequate immune response to covid-19 vaccination, 4500 mg
• Q0234 – Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg
• Q0235 – Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg
• Q0237 – Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
• Q0238 – Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
• Q0239 – Injection, bamlanivimab-xxxx, 700 mg
• Q0243 – Injection, casirivimab and imdevimab, 2400 mg
• Q0244 – Injection, casirivimab and imdevimab, 1200 mg
• Q0245 – Injection, bamlanivimab and etesevimab, 2100 mg
• Q0247 – Injection, sotrovimab, 500 mg
• Q0249 – Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
• Q0477 – Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only
• Q0478 – Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type
• Q0479 – Power module for use with electric or electric/pneumatic ventricular assist device, replacement only